Clinical Trial Update: Nebulised Heparin in Patients With Severe COVID-19 [Phase 2, Phase 3]

View source ↗

Summary

Update on a Phase 2/3 trial of nebulised heparin in patients with severe COVID-19 and respiratory failure. The study status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Failure

Drugs mentioned

• Nebulised heparin (heparin)

Snippet

Sponsor: Australian National University | Conditions: Covid19, Respiratory Failure | Phase 2, Phase 3 | Status: COMPLETED